biopharmaceutics-2018-scientifictracks

Page 26

Notes:

allied

academies

Asian Journal of Biomedical and Pharmaceutical Sciences | Volume 8

May 14-15, 2018 | Montreal, Canada

Global Summit on

Biopharma & Biotherapeutics

he breakthrough therapies with immuno-oncology

biologics aiming at stimulating the T-lymphocytes

targeting the specific tumor after identification of the

gene mutation pattern of the tumor using new generation

sequencing (NGS), aim at stopping tumor progression in first

instance then degenerating the tumor up-to complete drying-

off and disappearance. After the complete degeneration

of the tumor achieving a progression-free survival, the

corresponding organ can be regenerated using the patient’s

own skin- or fat cells, to obtain induced pluripotent stem

cells that regenerate the organ, this is in also relevant for

visible organs like in case of breast cancer. With the stem

cell therapy, deficient organs can be regenerated and human

longevity significantly prolonged. Combining degenerative

medicine with regenerativemedicine is a vision that becomes

reality.

Speaker Biography

Michel Mikhail has more than 30 years of pharmaceutical industry experience and

track record of achievement in R&D and international regulatory affairs in large

multinational research-based pharmaceutical as well as biotech companies. He is a

Chartered Expert in Pharmacology-Toxicology, a Chartered Clinical Expert as well as a

Chartered Analytical Expert. He has participated in the development of ICH guidelines,

served on the Safety Working Group and Efficacy Working Group of the European

Federation of Pharmaceutical Industry Associations (EFPIA) also as a Topic Leader. He

has served on the Regulatory Group of the European branch of the Pharmaceutical

Research and Manufacturers of America (PhRMA Europe). He is a Member of the

Expert Committee of the Governmental Federal Institute of Risk Assessment (BfR)

Germany and served as Member of the Expert Committee for Toxicology of the United

States Pharmacopoeia (USP).

How to combine degenerative medicine with regenerative medicine using biologics and cell therapies

Michel Mikhail

BioNTech AG, Germany